Related Experiment Video

Updated: May 19, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Access to biologic therapies in Canada for children with juvenile idiopathic arthritis

Claire M A Leblanc1, Bianca Lang, Alma Bencivenga

  • 1McGill University, and Department of Pediatrics, Montreal Children's Hospital, 2300 Rue Tupper, Montreal, Quebec H3H 1P3, Canada. claire.leblanc@muhc.mcgill.ca

The Journal of Rheumatology
|August 4, 2012
PubMed

Insights

Access to biologic therapies for children with juvenile idiopathic arthritis (JIA) in Canada is inconsistent, with significant provincial variations in coverage and criteria. This limits optimal care and necessitates policy reform for better health outcomes.

Area of Science:

  • Pediatric Rheumatology
  • Health Policy
  • Pharmacoeconomics

Background:

  • Juvenile idiopathic arthritis (JIA) is a chronic autoimmune disease affecting children.
  • Biologic therapies offer effective treatment options for JIA.
  • Access to these advanced treatments varies significantly within Canada.

Purpose of the Study:

  • To compare access to biologic therapies for pediatric JIA patients across Canadian provinces.
  • To identify provincial regulatory differences and access criteria for these treatments.

Main Methods:

  • Compilation of provincial reimbursement guidelines for JIA biologics (June-August 2010).
  • Multicenter, Canada-wide survey of pediatric rheumatologists regarding access experiences.
  • Analysis of discrepancies in access criteria and coverage.

Main Results:

  • Substantial difficulties were found in accessing biologic treatments, except for etanercept and abatacept.
  • Significant provincial discrepancies in access criteria and coverage were identified.
  • Age restrictions for younger children represented a notable barrier.

Conclusions:

  • Canadian children with JIA may not receive internationally recognized standard care due to limited and inconsistent provincial formulary coverage.
  • Urgent public policy changes are needed to improve access to biologic therapies.
  • Enhanced access is crucial for optimizing short-term and long-term health outcomes for children with JIA.
Abstract

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...